AR086398A1 - Canabinoides que pueden usarse en el tratamiento del dolor neuropatico - Google Patents

Canabinoides que pueden usarse en el tratamiento del dolor neuropatico

Info

Publication number
AR086398A1
AR086398A1 ARP120101707A ARP120101707A AR086398A1 AR 086398 A1 AR086398 A1 AR 086398A1 AR P120101707 A ARP120101707 A AR P120101707A AR P120101707 A ARP120101707 A AR P120101707A AR 086398 A1 AR086398 A1 AR 086398A1
Authority
AR
Argentina
Prior art keywords
neuropathic pain
canabinoids
treatment
phytocannabinoids
cannabidivarine
Prior art date
Application number
ARP120101707A
Other languages
English (en)
Inventor
Geoffrey Guy
Francesco Rossi
Tetsuro Kikuchi
Colin Stott
Sabatino Maione
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of AR086398A1 publication Critical patent/AR086398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Diversos canabinoides que pueden usarse para tratar el dolor neuropático, que preferiblemente son uno o más fitocanabinoides, tales como el canabigerol (CBG), el canabicromeno (CBC), la canabidivarina (CBDV) o la tetrahidrocanabivarina (THCV), y más preferiblemente son fitocanabinoides que han sido aislados y/o purificados a partir de extractos de plantas de Cannabis.
ARP120101707A 2011-05-20 2012-05-14 Canabinoides que pueden usarse en el tratamiento del dolor neuropatico AR086398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1108506.5A GB2491118B (en) 2011-05-20 2011-05-20 Cannabinoids for use in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
AR086398A1 true AR086398A1 (es) 2013-12-11

Family

ID=44279366

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101707A AR086398A1 (es) 2011-05-20 2012-05-14 Canabinoides que pueden usarse en el tratamiento del dolor neuropatico

Country Status (21)

Country Link
US (1) US9895342B2 (es)
EP (1) EP2709604B1 (es)
JP (1) JP6147249B2 (es)
KR (1) KR20140037124A (es)
CN (1) CN103533930A (es)
AR (1) AR086398A1 (es)
AU (1) AU2012260611B2 (es)
BR (1) BR112013029773A2 (es)
CA (1) CA2833099C (es)
CO (1) CO6811867A2 (es)
DK (1) DK2709604T3 (es)
EA (1) EA201391733A1 (es)
ES (1) ES2624308T3 (es)
GB (2) GB2491118B (es)
IL (1) IL229474B (es)
MX (1) MX2013013141A (es)
PT (1) PT2709604T (es)
SG (1) SG194839A1 (es)
TW (1) TW201249425A (es)
WO (1) WO2012160358A1 (es)
ZA (1) ZA201309364B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. METHOD AND COMPOSITIONS FOR TREATING REST-FREE LEG SYNDROME
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
WO2019056123A1 (en) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2019147690A1 (en) 2018-01-23 2019-08-01 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
KR102445087B1 (ko) * 2019-05-03 2022-09-20 자이우스 라이프 사이언시스 아이엔씨. 통증 관리용 제형
KR20230005266A (ko) * 2020-04-24 2023-01-09 자이우스 라이프 사이언시스 아이엔씨. 통증 관리용 칸나비크로멘 제제
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022218382A1 (zh) * 2021-04-14 2022-10-20 成都百裕制药股份有限公司 氘代苯酚衍生物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1494907A (zh) 1996-03-25 2004-05-12 治疗疼痛的药物组合物
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
DE10296335T5 (de) 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
ES2377819T3 (es) 2002-08-14 2012-04-02 Gw Pharma Limited Formulaciones líquidas cannabinoides para administración mucosal
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
EP1747786A3 (en) 2005-07-25 2007-04-25 Perdix Eurogroup S.L. Natural product in cream with anti-vitiligo therapeutic properties
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2517313A1 (en) * 2005-08-26 2007-02-26 Queen's University At Kingston Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors

Also Published As

Publication number Publication date
GB2491118B (en) 2015-12-30
PT2709604T (pt) 2017-05-17
CN103533930A (zh) 2014-01-22
DK2709604T3 (en) 2017-05-15
IL229474B (en) 2018-11-29
JP2014513715A (ja) 2014-06-05
ES2624308T3 (es) 2017-07-13
EA201391733A1 (ru) 2014-04-30
GB2524689B (en) 2016-01-27
WO2012160358A1 (en) 2012-11-29
BR112013029773A2 (pt) 2017-01-17
KR20140037124A (ko) 2014-03-26
IL229474A0 (en) 2014-01-30
ZA201309364B (en) 2015-04-29
CA2833099A1 (en) 2012-11-29
US9895342B2 (en) 2018-02-20
AU2012260611B2 (en) 2017-06-15
GB201108506D0 (en) 2011-07-06
EP2709604A1 (en) 2014-03-26
GB2491118A (en) 2012-11-28
CO6811867A2 (es) 2013-12-16
GB2524689A (en) 2015-09-30
GB201512357D0 (en) 2015-08-19
JP6147249B2 (ja) 2017-06-14
MX2013013141A (es) 2014-02-17
CA2833099C (en) 2020-11-03
NZ618246A (en) 2016-01-29
TW201249425A (en) 2012-12-16
US20140107192A1 (en) 2014-04-17
US20140378539A9 (en) 2014-12-25
AU2012260611A1 (en) 2013-12-12
EP2709604B1 (en) 2017-02-01
SG194839A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
AR086398A1 (es) Canabinoides que pueden usarse en el tratamiento del dolor neuropatico
AR088047A1 (es) Composicion farmaceutica que comprende a los fitocannabinoides cannabidivarina (cbdv) y cannabidiol (cbd)
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CO6280445A2 (es) Composicion que comprende un cladosporium y un portador para las esporas
CO2019014279A2 (es) Proceso para la purificación y separación de cannabinoides a partir de cáñamo seco y hojas de cannabis
EA201290975A8 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
BR112017010591A2 (pt) método para a preparação de uma fibra de viscose, e, fibra de viscose
CR20150326A (es) Inhibidores de autotaxina
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
NZ629136A (en) Phytocannabinoids in the treatment of cancer
GB2492487A8 (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT201400101A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
AR089155A1 (es) Unidad de procesamiento de isomerizacion y transalquilacion de xileno combinada
BR112015003742A2 (pt) sistema de montagem de componente de descarga
ECSP14030779A (es) Inhibidores del nampt
CO6710926A2 (es) Compuestos de n-heteroarilo
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GB201120067D0 (en) Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
CL2014000172A1 (es) Composicion en spray que comprende a) un portador de oxigeno, tal como hemoglobina o mioglobina; y b) al menos un ingrediente adicional; metodo para preparar la composicion; proceso para purificar un portador de oxigeno; y su uso para el tratamiento externo de heridas.
NZ730985A (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
BR112017004304A2 (pt) composições de pteroestilbeno tópicas para uso em tratamento de perda de função de barreira na pele induzidas por uv

Legal Events

Date Code Title Description
FB Suspension of granting procedure